Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind,
parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic
dermatitis.